Genmab AS
This article was originally published in Start Up
Executive Summary
Medarex of Princeton, New Jersey was so pleased with the incentive package it found in Copenhagen, Denmark that it decided to spin out Genmab to take advantage of the opportunity. Beyond capital, the company received vital introductions to the medical and clinical community there. The start-up, one of more than 15 companies to have licensed rights to Medarex's HuMAb-Mouse technology, has already taken one fully human antibody into clinical trials, and hopes to put three more there in 2001. Genmab is also seeking to in-license rights to other antibodies. Given the relatively low cost and rapid development time for antibodies versus small molecules, the company thinks it can afford to manage development of multiple candidates simultaneously.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.